Publication | Open Access

Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial

UrologySurgical OncologyOncologyGenitourinary CancerPembrolizumab MonotherapyImmune Checkpoint InhibitorCancer TreatmentPhase 2Medicine